



Attorney Docket No. VPI/00-122DIV2 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/626,356  
Confirmation No.: 1551  
Filing Date: July 24, 2003  
Examiner: Rebecca L. Anderson  
Group Art Unit: 1626  
Applicants: Michael Hale et al.  
For: ISOXAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK

January 25, 2007  
Cambridge, Massachusetts

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT**

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

- ☒ Copy(ies) of references Citation No(s). C9-C19 are attached.
- ☐ Copy(ies) of references Citation No(s). \_\_\_\_\_ was/were filed in application U.S. Application No(s). \_\_\_\_\_ filed \_\_\_\_\_, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. \_\_\_\_\_ is attached herewith.

- (b) ☒ No fee is believed due because:

- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☒ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.


Applicants: Michael Hale et al.  
Application No.: 10/626,356

- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

Applicants: Michael Hale et al.  
Application No.: 10/626,356

☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,



---

Daniel A. Pearson, Reg. No. 58,053  
Agent for Applicants  
Karen E. Brown, Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6790  
Fax: (617) 444-6483

Modified Form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application Number	10/626,356
Filing Date	July 24, 2003
First Named Inventor	Michael Hale et al.
Group Art Unit	1626
Examiner Name	Rebecca L. Anderson
Attorney Docket Number	VPI/00-122 DIV2 US

## U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

## OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C9	Chang, et al., "Role of cAMP-Dependent Pathway in Eosinophil Apoptosis and Survival," Cellular Immunology; 203;29-38 (2000).
	C10	Frey and Mulder, "TGF $\beta$ regulation of mitogen-activated protein kinases in human breast cancer cells," Cancer Letters, 117:41-50 (1997).
	C11	Fukunaga and Miyamoto, "Role of MAP Kinase in Neurons," Molecular Neurobiology, 16(1):79-95 (1998).
	C12	Hoshino, et al., "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors," Oncogene, 18:813-822 (1999).
	C13	Illenberger, et al., "The Endogenous and Cell Cycle-dependent Phosphorylation of tau Protein in Living Cells: Implications for Alzheimer's Disease," Molecular Biology of the Cell, 9:1495-1512 (June 1998).
	C14	Kodama, et al., "Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy," Am. J. Physiol Heart Circ Physiol, 279:H1635-H1644, (2000).
	C15	Kortylewski, et al., "Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells," Biochem J., 357:297-303, (2001).
	C16	Namura, et al., "Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia," PNAS, 98(20):11569-11574 (September 25, 2001).
	C17	Putz, et al., "Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines," Cancer Research, 59:227-233 (January 1, 1999).
	C18	Raghubandan and Ingram, "Hyperphosphorylation of the Cytoskeletal Protein Tau by the MAP-Kinase PK40erk2: Regulation by Prior Phosphorylation with cAMP-Dependent Protein Kinase A," Biochemical and Biophysical Research Communications, 215(3):1056-1066, (October 24, 1995).
	C19	Slevin, et al., "Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke," NeuroReport, 11(12):2759-2764 (August 21 2000).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.